Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2762755rdf:typepubmed:Citationlld:pubmed
pubmed-article:2762755lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2762755lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2762755lifeskim:mentionsumls-concept:C0030274lld:lifeskim
pubmed-article:2762755lifeskim:mentionsumls-concept:C0006639lld:lifeskim
pubmed-article:2762755lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:2762755lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:2762755lifeskim:mentionsumls-concept:C1516240lld:lifeskim
pubmed-article:2762755pubmed:issue5lld:pubmed
pubmed-article:2762755pubmed:dateCreated1989-9-15lld:pubmed
pubmed-article:2762755pubmed:abstractTextIt is well established that repeated injections of the cholecystokinin (CCK) analogue caerulein induce pancreatic hypersecretion and growth, but so far the time-specific development of hypersecretory capacity has not been studied. Rats were given intraperitoneal injections of caerulein (1 microgram/kg) three times daily for 0-7 days. On the day after the last injection a secretory test was performed with the rats under urethane anaesthesia. Subsequently, pancreatic tissue composition was analysed. Basal and caerulein-stimulated secretion rates of fluid and trypsin were elevated after as little as 1 day of caerulein treatment. These values remained significantly greater than those of the controls after 2-7 days' administration of the peptide. Pancreatic tissue hypertrophy (increases in absolute pancreatic weight, protein and trypsin contents, and also in these values normalized to DNA) appeared after 2 days' pretreatment. Tissue growth turned to hyperplasia (increase in tissue DNA content) after 5 days' caerulein administration. We conclude that chronic administration of the CCK analogue caerulein induces adaptation of the pancreas in a sequential order. First, the hypersecretory state appears, followed by hypertrophy, and, finally, pancreatic growth turns into hyperplasia.lld:pubmed
pubmed-article:2762755pubmed:languageenglld:pubmed
pubmed-article:2762755pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2762755pubmed:citationSubsetIMlld:pubmed
pubmed-article:2762755pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2762755pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2762755pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2762755pubmed:statusMEDLINElld:pubmed
pubmed-article:2762755pubmed:monthJunlld:pubmed
pubmed-article:2762755pubmed:issn0036-5521lld:pubmed
pubmed-article:2762755pubmed:authorpubmed-author:VargaGGlld:pubmed
pubmed-article:2762755pubmed:authorpubmed-author:PappMMlld:pubmed
pubmed-article:2762755pubmed:authorpubmed-author:DobronyiIIlld:pubmed
pubmed-article:2762755pubmed:issnTypePrintlld:pubmed
pubmed-article:2762755pubmed:volume24lld:pubmed
pubmed-article:2762755pubmed:ownerNLMlld:pubmed
pubmed-article:2762755pubmed:authorsCompleteYlld:pubmed
pubmed-article:2762755pubmed:pagination565-70lld:pubmed
pubmed-article:2762755pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:meshHeadingpubmed-meshheading:2762755-...lld:pubmed
pubmed-article:2762755pubmed:year1989lld:pubmed
pubmed-article:2762755pubmed:articleTitleTime-specific development of pancreatic hypersecretory capacity during chronic caerulein treatment in rats.lld:pubmed
pubmed-article:2762755pubmed:affiliationInstitute of Experimental Medicine, Hungarian Academy of Sciences, Budapest.lld:pubmed
pubmed-article:2762755pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2762755pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed